


## Uridine-<sup>15</sup>N<sub>2</sub>

<b>Cat. No.:</b>	HY-B1449S
<b>CAS No.:</b>	92487-68-8
<b>Molecular Formula:</b>	C <sub>9</sub> H <sub>12</sub> <sup>15</sup> N <sub>2</sub> O <sub>6</sub>
<b>Molecular Weight:</b>	246.19
<b>Target:</b>	Nucleoside Antimetabolite/Analog; Endogenous Metabolite
<b>Pathway:</b>	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (203.10 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	4.0619 mL	20.3095 mL	40.6190 mL
	5 mM	0.8124 mL	4.0619 mL	8.1238 mL
	10 mM	0.4062 mL	2.0310 mL	4.0619 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Uridine-<sup>15</sup>N<sub>2</sub> is the <sup>15</sup>N labeled Uridine[1].

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA